BioCentury | Oct 31, 2011
Company News

InNexus management update

InNexus Biotechnology Inc. (TSX-V:IXS; Pink:IXSBF), Vancouver, B.C. Business: Antibodies Hired: Angela Giannoccaro as CFO, formerly a public accountant WIR Staff...
BioCentury | May 16, 2011
Financial News

InNexus financial update

...million common shares inadvertently issued during the last three quarters of 2010 to repay debt. InNexus...
...issued at a price less than the Toronto Stock Exchange-Venture established minimum amount of C$0.05. InNexus Biotechnology Inc....
BioCentury | May 16, 2011
Company News

InNexus management update

InNexus Biotechnology Inc. (TSX-V:IXS; Pink:IXSBF), Vancouver, B.C. Business: Antibodies Hired: Christie Amato as CFO; she replaces David Petulla WIR Staff...
BioCentury | Mar 21, 2011
Company News

InNexus management update

InNexus Biotechnology Inc. (TSX-V:IXS; Pink:IXSBF), Vancouver, B.C. Business: Antibodies Hired: Jonathan Drutz as business development director, formerly president and CEO of consulting firm Biodealflow LLC WIR Staff...
BioCentury | Jul 12, 2010
Company News

InNexus, NIH deal

...NCI) amended a May deal to give InNexus access to additional immunotoxins to treat cancer. InNexus...
...the immunotoxins. NCI will evaluate the modified toxins against the unmodified version(see BioCentury, June 7). InNexus Biotechnology Inc....
BioCentury | Jun 7, 2010
Company News

InNexus, NIH deal

...InNexus and NIH's National Cancer Institute (NCI) will use InNexus' Dynamic Cross Linking (DXL) antibody technology...
...Linking (DXL) antibody technology to develop immunotoxins to treat cancer. Further terms were not disclosed. InNexus Biotechnology Inc....
BioCentury | Mar 29, 2010
Clinical News

InNexus preclinical data

...a humanized mAb against CD20 . Data were published in the Journal of Anti-Cancer Drugs. InNexus Biotechnology Inc....
BioCentury | Dec 21, 2009
Company News

InNexus, Xeris Pharmaceuticals Inc. deal

...The companies will use Xeris' formulation injection technology to develop InNexus' antibodies for subcutaneous injection. The...
...formulation and injection system, and InNexus will manufacture the antibodies. Further terms were not disclosed. InNexus Biotechnology Inc....
BioCentury | Jan 19, 2009
Clinical News

InNexus preclinical data

...be presented at the American Association for Cancer Research (AACR) conference in Denver in April. InNexus Biotechnology Inc....
BioCentury | Aug 11, 2008
Clinical News

InNexus preclinical data

...RA) in the U.S., and Roche (SWX:ROG, Basel, Switzerland) markets it elsewhere as MabThera . InNexus Biotechnology Inc....
Items per page:
1 - 10 of 46
BioCentury | Oct 31, 2011
Company News

InNexus management update

InNexus Biotechnology Inc. (TSX-V:IXS; Pink:IXSBF), Vancouver, B.C. Business: Antibodies Hired: Angela Giannoccaro as CFO, formerly a public accountant WIR Staff...
BioCentury | May 16, 2011
Financial News

InNexus financial update

...million common shares inadvertently issued during the last three quarters of 2010 to repay debt. InNexus...
...issued at a price less than the Toronto Stock Exchange-Venture established minimum amount of C$0.05. InNexus Biotechnology Inc....
BioCentury | May 16, 2011
Company News

InNexus management update

InNexus Biotechnology Inc. (TSX-V:IXS; Pink:IXSBF), Vancouver, B.C. Business: Antibodies Hired: Christie Amato as CFO; she replaces David Petulla WIR Staff...
BioCentury | Mar 21, 2011
Company News

InNexus management update

InNexus Biotechnology Inc. (TSX-V:IXS; Pink:IXSBF), Vancouver, B.C. Business: Antibodies Hired: Jonathan Drutz as business development director, formerly president and CEO of consulting firm Biodealflow LLC WIR Staff...
BioCentury | Jul 12, 2010
Company News

InNexus, NIH deal

...NCI) amended a May deal to give InNexus access to additional immunotoxins to treat cancer. InNexus...
...the immunotoxins. NCI will evaluate the modified toxins against the unmodified version(see BioCentury, June 7). InNexus Biotechnology Inc....
BioCentury | Jun 7, 2010
Company News

InNexus, NIH deal

...InNexus and NIH's National Cancer Institute (NCI) will use InNexus' Dynamic Cross Linking (DXL) antibody technology...
...Linking (DXL) antibody technology to develop immunotoxins to treat cancer. Further terms were not disclosed. InNexus Biotechnology Inc....
BioCentury | Mar 29, 2010
Clinical News

InNexus preclinical data

...a humanized mAb against CD20 . Data were published in the Journal of Anti-Cancer Drugs. InNexus Biotechnology Inc....
BioCentury | Dec 21, 2009
Company News

InNexus, Xeris Pharmaceuticals Inc. deal

...The companies will use Xeris' formulation injection technology to develop InNexus' antibodies for subcutaneous injection. The...
...formulation and injection system, and InNexus will manufacture the antibodies. Further terms were not disclosed. InNexus Biotechnology Inc....
BioCentury | Jan 19, 2009
Clinical News

InNexus preclinical data

...be presented at the American Association for Cancer Research (AACR) conference in Denver in April. InNexus Biotechnology Inc....
BioCentury | Aug 11, 2008
Clinical News

InNexus preclinical data

...RA) in the U.S., and Roche (SWX:ROG, Basel, Switzerland) markets it elsewhere as MabThera . InNexus Biotechnology Inc....
Items per page:
1 - 10 of 46